Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:59 ET | 100 | 4.75 |
10:19 ET | 120 | 4.8464 |
10:26 ET | 100 | 4.815 |
11:11 ET | 100 | 4.845 |
11:15 ET | 100 | 4.75 |
11:38 ET | 200 | 4.84 |
11:42 ET | 100 | 4.835 |
11:45 ET | 100 | 4.835 |
11:49 ET | 100 | 4.835 |
12:00 ET | 100 | 4.815 |
12:03 ET | 100 | 4.83 |
12:05 ET | 100 | 4.83 |
12:07 ET | 100 | 4.83 |
12:14 ET | 100 | 4.8125 |
12:20 ET | 100 | 4.8125 |
12:25 ET | 4024 | 4.7355 |
12:41 ET | 100 | 4.79 |
12:48 ET | 200 | 4.8 |
01:03 ET | 4998 | 4.7297 |
01:10 ET | 400 | 4.6767 |
01:12 ET | 100 | 4.755 |
01:19 ET | 100 | 4.76 |
01:26 ET | 100 | 4.82 |
01:30 ET | 100 | 4.8499 |
01:32 ET | 100 | 4.8 |
01:35 ET | 100 | 4.8 |
01:39 ET | 100 | 4.8 |
01:42 ET | 100 | 4.82 |
01:46 ET | 100 | 4.8 |
01:48 ET | 400 | 4.83 |
01:50 ET | 200 | 4.8 |
01:55 ET | 100 | 4.79 |
01:57 ET | 600 | 4.79 |
02:00 ET | 335 | 4.8 |
02:02 ET | 4783 | 4.8 |
02:27 ET | 100 | 4.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 215.2M | -7.6x | --- |
Zura Bio Ltd | 215.3M | -2.0x | --- |
Actinium Pharmaceuticals Inc | 213.2M | -4.3x | --- |
Skye Bioscience Inc | 221.2M | -1.7x | --- |
Eliem Therapeutics Inc | 208.6M | -14.0x | --- |
Prelude Therapeutics Inc | 208.2M | -1.9x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $215.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.81 |
EPS | $-0.63 |
Book Value | $3.30 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.